Monocyte-derived dendritic cell differentiation
Materials Required
Principle
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state[1][2][3][4][5][6][7]. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail[1][3][7][8][9].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use human peripheral blood mononuclear cells or leukocyte-enriched blood products as the starting material, monocyte-enrichment methods such as plastic adherence, FBS-coated flask adherence, density-gradient/Percoll-based enrichment, or magnetic bead enrichment, and culture medium such as RPMI-based medium for monocyte culture and MoDC differentiation[2][3][4][5][6][9].
• Use recombinant human GM-CSF and recombinant human IL-4 to drive monocyte-to-MoDC differentiation; reported effective concentrations include 400 U/mL for both cytokines in an FBS-coated-flask protocol and 500 IU/mL for both cytokines in a semi-adherent RPMI culture protocol[5][6].
• For optional maturation, use literature-supported maturation stimuli such as TNF-α alone or the cytokine/PGE2 cocktail containing TNF-α, IL-1β, IL-6, and PGE2, which has been reported to induce uniform maturation of human monocyte-derived dendritic cells[3][7][8].
• Use flow-cytometry antibodies against CD14 to assess monocyte identity or residual monocyte phenotype, CD209 or CD1a to assess immature MoDC differentiation, and CD83, CD80, CD86, and HLA-DR to assess maturation and antigen-presenting phenotype[5][6][9].
• Use FITC-dextran or dextran uptake assays when antigen-uptake function is required, because GM-CSF/IL-4-cultured monocytes have been assessed by increased dextran uptake during immature DC differentiation[1][7].
• Use sterile tissue-culture plates or flasks for monocyte culture, FBS-coated flasks when applying the adherence protocol, magnetic separation equipment when applying bead-based enrichment, a CO2 cell-culture incubator, a centrifuge for PBMC preparation, an inverted microscope for morphology monitoring, and a flow cytometer for CD14, CD209/CD1a, CD83, CD80, CD86, and HLA-DR analysis[4][5][6][9].
• Use recombinant human GM-CSF and recombinant human IL-4 to drive monocyte-to-MoDC differentiation; reported effective concentrations include 400 U/mL for both cytokines in an FBS-coated-flask protocol and 500 IU/mL for both cytokines in a semi-adherent RPMI culture protocol[5][6].
• For optional maturation, use literature-supported maturation stimuli such as TNF-α alone or the cytokine/PGE2 cocktail containing TNF-α, IL-1β, IL-6, and PGE2, which has been reported to induce uniform maturation of human monocyte-derived dendritic cells[3][7][8].
• Use flow-cytometry antibodies against CD14 to assess monocyte identity or residual monocyte phenotype, CD209 or CD1a to assess immature MoDC differentiation, and CD83, CD80, CD86, and HLA-DR to assess maturation and antigen-presenting phenotype[5][6][9].
• Use FITC-dextran or dextran uptake assays when antigen-uptake function is required, because GM-CSF/IL-4-cultured monocytes have been assessed by increased dextran uptake during immature DC differentiation[1][7].
• Use sterile tissue-culture plates or flasks for monocyte culture, FBS-coated flasks when applying the adherence protocol, magnetic separation equipment when applying bead-based enrichment, a CO2 cell-culture incubator, a centrifuge for PBMC preparation, an inverted microscope for morphology monitoring, and a flow cytometer for CD14, CD209/CD1a, CD83, CD80, CD86, and HLA-DR analysis[4][5][6][9].
Experimental Procedure
• Prepare PBMCs from human blood or leukocyte-enriched blood products using a peer-reviewed PBMC isolation workflow, then enrich monocytes using a selected literature-supported method: adherence-based enrichment, FBS-coated-flask adherence, Percoll-based enrichment, or magnetic bead enrichment[2][3][4][5][6][9].
• For higher viability and lymphocyte depletion, magnetic bead monocyte enrichment is supported by comparative data showing viability above 95% and stronger lymphocyte depletion than cold aggregation or Percoll enrichment; for a lower-cost adherence approach, FBS-coated flasks can be used, with overnight incubation reported to give higher monocyte purity than shorter adherence in one comparative protocol[5][6].
• Prepare differentiation medium with recombinant human GM-CSF plus recombinant human IL-4; use either 400 U/mL each when following the FBS-coated-flask optimization study or 500 IU/mL each when following the RPMI semi-adherent optimization study[5][6].
• Seed enriched monocytes into sterile cultureware under the selected validated culture format, then culture with GM-CSF plus IL-4 to generate immature MoDCs; conventional MoDC generation is reported as requiring approximately 5-7 days of GM-CSF/IL-4 differentiation before maturation, although 48-hour FastDC strategies have also been reported[3][5][6][7].
• For the conventional differentiation route, maintain monocytes in GM-CSF plus IL-4 culture until immature MoDCs are obtained, then harvest loosely adherent or non-adherent dendritic-cell-like cells for phenotyping or for maturation; reported successful readouts include CD14 reduction and increased CD209, CD1a, HLA-DR, CD80, and CD86 depending on the study[1][2][3][5][6][9].
• For a rapid route, culture monocytes with GM-CSF plus IL-4 for 24 hours, then expose cells to pro-inflammatory maturation mediators for another 24 hours; this FastDC strategy was reported to produce mature dendritic cells within 48 hours and was associated with CD14 downregulation, increased dextran uptake at the immature stage, and mature DC characteristics after activation[7].
• For optional maturation after conventional differentiation, expose immature MoDCs to a maturation stimulus supported in the literature, such as TNF-α or a TNF-α/IL-1β/IL-6/PGE2 cocktail; the cytokine/PGE2 cocktail has been reported to yield uniform maturation of human MoDCs and is commonly assessed by CD83, CD80, CD86, and HLA-DR expression[3][8].
• Analyze cells by flow cytometry using CD14 as the monocyte/residual monocyte marker, CD209 or CD1a as MoDC differentiation markers, and CD83, CD80, CD86, and HLA-DR as maturation or antigen-presentation markers; compare day-0 monocytes, immature MoDCs, mature MoDCs, unstained cells, and isotype or fluorescence-minus-one controls where used by the selected flow-cytometry workflow[5][6][9].
• Interpret successful immature MoDC differentiation as reduced CD14 together with increased dendritic-cell marker expression and/or dextran uptake, and interpret successful maturation as increased CD83, CD80, CD86, and HLA-DR relative to immature MoDCs[1][5][6][7][8][9].
• For higher viability and lymphocyte depletion, magnetic bead monocyte enrichment is supported by comparative data showing viability above 95% and stronger lymphocyte depletion than cold aggregation or Percoll enrichment; for a lower-cost adherence approach, FBS-coated flasks can be used, with overnight incubation reported to give higher monocyte purity than shorter adherence in one comparative protocol[5][6].
• Prepare differentiation medium with recombinant human GM-CSF plus recombinant human IL-4; use either 400 U/mL each when following the FBS-coated-flask optimization study or 500 IU/mL each when following the RPMI semi-adherent optimization study[5][6].
• Seed enriched monocytes into sterile cultureware under the selected validated culture format, then culture with GM-CSF plus IL-4 to generate immature MoDCs; conventional MoDC generation is reported as requiring approximately 5-7 days of GM-CSF/IL-4 differentiation before maturation, although 48-hour FastDC strategies have also been reported[3][5][6][7].
• For the conventional differentiation route, maintain monocytes in GM-CSF plus IL-4 culture until immature MoDCs are obtained, then harvest loosely adherent or non-adherent dendritic-cell-like cells for phenotyping or for maturation; reported successful readouts include CD14 reduction and increased CD209, CD1a, HLA-DR, CD80, and CD86 depending on the study[1][2][3][5][6][9].
• For a rapid route, culture monocytes with GM-CSF plus IL-4 for 24 hours, then expose cells to pro-inflammatory maturation mediators for another 24 hours; this FastDC strategy was reported to produce mature dendritic cells within 48 hours and was associated with CD14 downregulation, increased dextran uptake at the immature stage, and mature DC characteristics after activation[7].
• For optional maturation after conventional differentiation, expose immature MoDCs to a maturation stimulus supported in the literature, such as TNF-α or a TNF-α/IL-1β/IL-6/PGE2 cocktail; the cytokine/PGE2 cocktail has been reported to yield uniform maturation of human MoDCs and is commonly assessed by CD83, CD80, CD86, and HLA-DR expression[3][8].
• Analyze cells by flow cytometry using CD14 as the monocyte/residual monocyte marker, CD209 or CD1a as MoDC differentiation markers, and CD83, CD80, CD86, and HLA-DR as maturation or antigen-presentation markers; compare day-0 monocytes, immature MoDCs, mature MoDCs, unstained cells, and isotype or fluorescence-minus-one controls where used by the selected flow-cytometry workflow[5][6][9].
• Interpret successful immature MoDC differentiation as reduced CD14 together with increased dendritic-cell marker expression and/or dextran uptake, and interpret successful maturation as increased CD83, CD80, CD86, and HLA-DR relative to immature MoDCs[1][5][6][7][8][9].
Troubleshooting
Problem: Low MoDC differentiation, shown by persistent CD14 and weak CD209 expression.
• Possible Cause: Culture conditions may not match the optimized semi-adherent RPMI condition.• Literature-supported Solution: Use RPMI medium with GM-CSF and IL-4 at 500 IU/mL each in a semi-adherent culture format, which produced better differentiation with increased CD209 and lower CD14 in a comparative protocol study[5].
Problem: Low viability after monocyte enrichment.
• Possible Cause: Percoll-based enrichment can reduce viability.• Literature-supported Solution: Use magnetic bead enrichment when viability is critical, because one comparative study reported viability above 95% with magnetic bead enrichment, whereas Percoll enrichment produced lower viability[5].
Problem: Low monocyte purity after adherence enrichment.
• Possible Cause: Short adherence may not enrich monocytes as effectively as longer FBS-coated-flask adherence.• Literature-supported Solution: Use overnight incubation on FBS-coated flasks when prioritizing purity, because this condition showed the highest monocyte purity in the FBS-coated-flask comparison[6].
Problem: Immature phenotype after differentiation when mature MoDCs are required.
• Possible Cause: GM-CSF plus IL-4 differentiation generates immature MoDCs unless a maturation stimulus is added.• Literature-supported Solution: Add a supported maturation stimulus such as TNF-α or TNF-α/IL-1β/IL-6/PGE2 and confirm maturation by CD83, CD80, CD86, and HLA-DR flow cytometry[3][7][8].
参考文献:
- [1]. Sallusto F, et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109-1118. [Content Brief]
- [2]. Bender A, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196(2):121-135. [Content Brief]
- [3]. Romani N, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196(2):137-151. [Content Brief]
- [4]. Nair S, et al. Isolation and generation of human dendritic cells. Curr Protoc Immunol. 2012;Chapter 7:Unit7.32. [Content Brief]
- [5]. Chometon TQ, et al. A protocol for rapid monocyte isolation and generation of singular human monocyte-derived dendritic cells. PLoS One. 2020;15(4):e0231132. [Content Brief]
- [6]. Meskini M, et al. A protocol to isolate and characterize pure monocytes and generate monocyte-derived dendritic cells through FBS-coated flasks. Sci Rep. 2024;14(1):23956. [Content Brief]
- [7]. Dauer M, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170(8):4069-4076. [Content Brief]
- [8]. Lee AW, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20 Suppl 4:A8-A22. [Content Brief]
- [9]. Figueroa G, et al. Characterization of human monocyte-derived dendritic cells by imaging flow cytometry: a comparison between two monocyte isolation protocols. J Vis Exp. 2016;(116):54296. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail